I. Vonkugelgen et K. Starke, KAINATE RECEPTORS ARE INVOLVED IN THE GLUTAMATE-INDUCED INDIRECT, PURINERGIC INHIBITION OF [H-3] NORADRENALINE RELEASE IN RABBIT BRAIN CORTEX, Naunyn-Schmiedeberg's archives of pharmacology, 353(1), 1995, pp. 46-54
Activation of ionotropic but not of metabotropic glutamate receptors c
auses an indirect inhibition of the release of noradrenaline in slices
of rabbit brain cortex. The inhibition is mediated by adenosine which
activates presynaptic adenosine A(1)-receptors. The present study cha
racterizes the ionotropic receptor types through which glutamate itsel
f produces this indirect inhibition. Rabbit brain cortex slices were p
reincubated with [H-3]-noradrenaline, superfused with medium containin
g desipramine (1 mu M) and stimulated electrically by trains of 6 puls
es at 100 Hz. Glutamate (100-3000 mu M) reduced the electrically evoke
d overflow of tritium by up to 58%. The effect did not differ 20 min a
nd 60 min after addition of glutamate. Adenosine deaminase (1 U ml(-1)
) as well as 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 30 mu M) and
D-gamma-glutamylamino-methanesulfonate (GAMS; 30 mu M), both of which
block kainate receptors, attenuated the glutamate-induced inhibition.
The NMDA receptor antagonist 2-amino-5-phosphonopentanoate (AP5; 100 m
u M) and the AMPA receptor antagonist 6-nitro-7-sulfamoylbenzo(f)quino
xaline-2,3-dione (NBQX; 30 mu M) did not change the effect of glutamat
e. Given alone, CNQX and GAMS, but not AP5 and NBQX, slightly increase
d the evoked overflow of tritium; the increases were abolished in the
presence of adenosine deaminase. The results indicate that activation
of kainate but not NMDA and AMPA receptors is involved in the indirect
, adenosine-mediated inhibition by exogenous glutamate of the release
of noradrenaline in rabbit brain cortex slices. Moreover, as shown by
the increase caused by CNQX and GAMS, endogenous excitatory amino acid
s inhibit the release of noradrenaline through the kainate receptor-ad
enosine mechanism and thus contribute to the purinergic inhibitory con
trol of noradrenaline release in the brain.